Experimental "armored" CAR T cell therapy for non-Hodgkin lymphoma shows 80% overall response rate in Phase I trial.
Experimental "armored" CAR T cell therapy shows promise for difficult-to-treat cancers like non-Hodgkin lymphoma (NHL). In a Phase I clinical trial, the new therapy, developed by Carl June at the University of Pennsylvania, was found to be safe with a three-month overall response rate of 80% in patients with relapsed or resistant NHL after receiving a commercially available CAR T cell therapy.
June 01, 2024
4 Articles